Literature DB >> 15259083

Empirical antibiotic treatment with piperacillin-tazobactam in patients with microbiologically-documented biliary tract infections.

Gabrio Bassotti1, Fabio Chistolini, Francis Sietchiping-Nzepa, Giuseppe De-Roberto, Antonio Morelli.   

Abstract

AIM: To report our experience with empiric antimicrobial monotherapy (piperacillin/tazobactam, of which no data are available in such specific circumstances) in microbiologically-documented infections in patients with benign and malignant conditions of the biliary tract.
METHODS: Twenty-three patients, 10 with benign and 13 with malignant conditions affecting the biliary tree and microbiologically-documented infections were recruited and the efficacy of empirical antibiotic therapy was assessed.
RESULTS: The two groups featured similar demographic and clinical data. Overall, the infective episodes were most due to Gram negative agents, more than 60% of such episodes (mostly in malignant conditions) were preceded by invasive instrumental maneuvers. Empirical antibiotic therapy with a single agent (piperacillin/tazobactam) was effective in more than 80% of cases. No deaths were reported following infections.
CONCLUSION: An empiric therapeutic approach with piperacillin/tazobactam is highly effective in biliary tract infections due to benign or malignant conditions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15259083      PMCID: PMC4724983          DOI: 10.3748/wjg.v10.i15.2281

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  28 in total

Review 1.  Antibiotic therapy in intra-abdominal infections--a review on randomised clinical trials.

Authors:  R G Holzheimer; H Dralle
Journal:  Eur J Med Res       Date:  2001-07-30       Impact factor: 2.175

2.  Assessment of biliary excretion of piperacillin-tazobactam in humans.

Authors:  J F Westphal; J M Brogard; F Caro-Sampara; M Adloff; J F Blicklé; H Monteil; F Jehl
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Induced antibiotic-resistant bacteria in cholangitis with biliary stasis.

Authors:  B Demediuk; A G Speer; A Hellyar
Journal:  Aust N Z J Surg       Date:  1996-11

Review 4.  Pharmacokinetic characteristics of piperacillin/tazobactam.

Authors:  F Sörgel; M Kinzig
Journal:  Intensive Care Med       Date:  1994-07       Impact factor: 17.440

5.  Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infection.

Authors:  E S Dietrich; B Schubert; W Ebner; F Daschner
Journal:  Pharmacoeconomics       Date:  2001-01       Impact factor: 4.981

6.  Microbiological analysis of sepsis complicating non-surgical biliary drainage in malignant obstruction.

Authors:  J G Levine; J Botet; R C Kurtz
Journal:  Gastrointest Endosc       Date:  1990 Jul-Aug       Impact factor: 9.427

7.  Microbiology of bile in patients with cholangitis or cholestasis with and without plastic biliary endoprosthesis.

Authors:  Rungsun Rerknimitr; Evan L Fogel; Cem Kalayci; Edward Esber; Glen A Lehman; Stuart Sherman
Journal:  Gastrointest Endosc       Date:  2002-12       Impact factor: 9.427

8.  Antibiotic susceptibility profiles of 941 gram-negative bacteria isolated from septicemic patients throughout Canada. The Canadian Study Group.

Authors:  S Chamberland; J L'Ecuyer; C Lessard; M Bernier; P Provencher; M G Bergeron
Journal:  Clin Infect Dis       Date:  1992-10       Impact factor: 9.079

Review 9.  Azlocillin, mezlocillin, and piperacillin: new broad-spectrum penicillins.

Authors:  G M Eliopoulos; R C Moellering
Journal:  Ann Intern Med       Date:  1982-11       Impact factor: 25.391

10.  Prospective randomized comparison of mezlocillin therapy alone with combined ampicillin and gentamicin therapy for patients with cholangitis.

Authors:  W B Gerecht; N K Henry; W W Hoffman; S M Muller; N F LaRusso; J E Rosenblatt; W R Wilson
Journal:  Arch Intern Med       Date:  1989-06
View more
  2 in total

1.  Contemporary Management of Biliary Tract Infections.

Authors:  Josh George; John Baillie
Journal:  Curr Infect Dis Rep       Date:  2005-03       Impact factor: 3.725

2.  Clinical efficacy of intravenous doripenem in patients with acute biliary tract infection: a multicenter, randomized, controlled trial with imipenem/cilastatin as comparator.

Authors:  Susumu Tazuma; Yoshinori Igarashi; Kazuo Inui; Hirotaka Ohara; Toshio Tsuyuguchi; Shomei Ryozawa
Journal:  J Gastroenterol       Date:  2014-05-03       Impact factor: 7.527

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.